Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-3 and MET-5 in Hypertriglyceridemia
NCT04507971Phase 1Unknown
- Sponsor
- NuBiyota
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial in hypertriglyceridemia and obesity comparing MET-3 with MET-5 (2 arms). Primary endpoint: Fasting blood lipid levels at Week 7. Status: unknown.
02
Drugs
MET-3MET-5
03
Conditions
hypertriglyceridemiaobesity
Beyond the preview
Go deeper on NCT04507971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507971.